Date: 2013-12-11
Type of information: Licensing agreement
Compound: POTELLIGENT® CHOK1SV
Company: BioWa (Japan) Lonza (Switzerland) Medimmune (USA - global biologics arm of AstraZeneca (UK)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: POTELLIGENT® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza’s proprietary GS Gene Expression System™, which includes the industry-leading CHOK1SV cell line. This technology is designed to improve the potency and efficacy of therapeutic antibodies by enhancing antibody-dependent cellular cytotoxicity (ADCC).
Disease:
Details: * On December 11, 2013, BioWa and Lonza have announced that they have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. MedImmune has licensed the companies’ POTELLIGENT® CHOK1SV Cell Line Technology for use in multiple proprietary antibodies in its pipeline.MedImmune entered into a previous licensing agreement with BioWa in 2007 for POTELLIGENT® Technology. This new agreement incorporates Lonza’s technology to the existing POTELLIGENT® Technology.
Financial terms:
Latest news:
